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ABSTRACT
Healthcare managers, clinical researchers and
individual patients (and their physicians) manage
variation differently to achieve different ends. First,
managers are primarily concerned with the
performance of care processes over time. Their time
horizon is relatively short, and the improvements they
are concerned with are pragmatic and ‘holistic.’ Their
goal is to create processes that are stable and
effective. The analytical techniques of statistical
process control effectively reﬂect these concerns.
Second, clinical and health-services researchers are
interested in the effectiveness of care and the
generalisability of ﬁndings. They seek to control
variation by their study design methods. Their primary
question is: ‘Does A cause B, everything else being
equal?’ Consequently, randomised controlled trials
and regression models are the research methods of
choice. The focus of this reductionist approach is on
the ‘average patient’ in the group being observed
rather than the individual patient working with the
individual care provider. Third, individual patients are
primarily concerned with the nature and quality of
their own care and clinical outcomes. They and
their care providers are not primarily seeking to
generalise beyond the unique individual. We propose
that the gold standard for helping individual
patients with chronic conditions should be longitudinal
factorial design of trials with individual patients.
Understanding how these three groups deal differently
with variation can help appreciate these three
approaches.
INTRODUCTION
Health managers, clinical researchers, and
individual patients need to understand and
manage variation in healthcare processes in
different time frames and in different ways.
In short, they ask different questions about
why and how healthcare processes and
outcomes change (table 1). Confusing the
needs of these three stakeholders results in
misunderstanding.
HEALTH MANAGERS
Our extensive experience in working with
healthcare managers has taught us that their
primary goal is to maintain and improve the
quality of care processes and outcomes for
groups of patients. Ongoing care and its
improvement are temporal, so in their situa-
tion, learning from variation over time is
essential. Data are organised over time to
answer the fundamental management ques-
tion: is care today as good as or better than it
was in the past, and how likely is it to be
better tomorrow? In answering that question,
it becomes crucial to understand the differ-
ence between common-cause and special-
cause variation (as will be discussed later).
Common-cause variation appears as random
variation in all measures from healthcare
processes.
1 Special-cause variation appears as
the effect of causes outside the core processes
of the work. Management can reduce this
variation by enabling the easy recognition of
special-cause variation and by changing
healthcare processesdby supporting the
use of clinical practice guidelines, for
exampledbut common-cause variation can
never be eliminated.
The magnitude of common-cause variation
creates the upper and lower control limits in
Shewhart control charts.
2e5 Such charts
summarise the work of health managers well.
Figure 1 shows a Shewhart control chart
(p-chart) developed by a quality-improvement
team whose aim was to increase compliance
with a new care protocol. The clinical records
of eligible patients discharged (45e75
patients) were evaluated each week by the
team, and records indicating that the
complete protocol was followed were identi-
ﬁed. The baseline control chart showed
a stable process with a centre line (average
performance) of 38% compliance. The team
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Discovering and deﬁning sources of evidenceanalysed the aspects of the protocol that were not
followed and developed process changes to make it
easier to complete these particular tasks. After success-
fully adapting the changes to the local environment
(indicated by weekly points above the upper control
limit in the ‘Implementing Changes’ period), the team
formally implemented the changes in each unit. The
team continued to monitor the process and eventually
developed updated limits for the chart. The updated
chart indicated a stable process averaging 83%.
This control chart makes it clear that a stable but
inferior process was operating for the ﬁrst 11 weeks and,
by inference, probably before that. The annotated
changes (testing, adapting and implementing new
processes of care) are linked to designed tests of change
which are special (assignable) causes of variation, in this
case, to improvement after week 15, after which a new
better stable process has taken hold. Note that there is
common-cause (random) variation in both the old and
improved processes.
After updating the control limits, the chart reveals
a new stable process with no special-cause variation,
which is to say, no points above or below thecontrol limits
(the dotted lines). Note that the change after week 15
cannot easily be explained by chance (random, or
common-cause, variation), since the probability of 13
points in a row occurring by chance above the baseline
control limit is one divided by 2 to the 13th power. This is
the same likelihood that in ﬂipping a coin 13 times, it will
come up heads every time. This level of statistical power
to exclude randomness as an explanation is not to be
found in randomised controlled trials (RCTs). Although
there is no hard-and-fast rule about the number of
observations over time needed to demonstrate process
stability and establish change, we believe a persuasive
control chart requires 20e30 or more observations.
The manager’s task demonstrates several important
characteristics. First is the need to deﬁne the key quality
characteristics, and choose among them for focused
improvement efforts. The choice should be made based
on the needs of patients and families. The importance of
these quality characteristics to those being served means
that speed in learning and improvement is important.
Indeed, for the healthcare manager, information for
improvement must be as rapid as possible (in real time).
Year-old research data are not very helpful here; just-in-
time performance data in the hands of the decision-
makers provide a potent opportunity for rapid
improvement.
6
Second, managerial change is holistic; that is, every
element of an intervention that might help to improve
and can be done is put to use, sometimes incrementally,
but simultaneously if need be. Healthcare managers are
actively working to promote measurement of process
and clinical outcomes, take problems in organisational
performance seriously, consider the root causes of
those problems, encourage the formation of problem
solving clinical micro-system teams and promote the
use of multiple, evolving PlaneDoeStudyeAct (PDSA)
tests of change.
This kind of improvement reasoning can be applied to
a wide range of care processes, large and small. For
example, good surgery is the appropriate combination
of hundreds of individual tasks, many of which could be
improved in small ways. Aggregating these many smaller
changes may result in important, observable improve-
ment over time. The protocol-driven, randomised trial
research approach is a powerful tool for establishing
efﬁcacy but has limitations for evaluating and improving
such complex processes as surgery, which are continually
and purposefully changing over time. The realities of
clinical improvement call for a move from after-the-fact
Table 1 Meaning of variation to managers, researchers and individual patients: questions, methods and time frames
Role Question Methods Time frame Variation
Health managers Are we getting better? Control charts, holistic
change
Real time, months’
variation
Creating stable processes,
learning from special cause
Clinical and
health-services
researchers
Other things equal,
does A cause B?
Randomised controlled
trials, regression models;
reductionist
Not urgent, years Eliminate special-cause
variation, test for signiﬁcance,
focus on mean values
Individual patient
(and provider)
How can I get better? Longitudinal, factorial
designs
Days, weeks,
lifelong
Help in understanding
the many reasons for
variation in health
Figure 1 Annotated Shewhart control chartdusing protocol.
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Discovering and deﬁning sources of evidencequality inspection to building quality measures into
medical information systems, thereby creating real-time
quality data for providers to act upon. Caring for popu-
lations of similar patients in similar ways (economies of
scale) can be of particular value, because the resulting
large numbers and process stability can help rapidly
demonstrate variation in care processes
7; very tight
control limits (minimal common-cause variation) allow
special-cause variation to be detected more quickly.
CLINICAL AND HEALTH-SERVICES RESEARCHERS
While quality-management thinking tends towards the
use of data plotted over time in control-chart format,
clinical researchers think in terms of true experimental
methods, such as RCTs. Health-services researchers, in
contrast, think in terms of regression analysis as their
principal tool for discovering explainable variation in
processes and outcomes of care. The data that both
communities of researchers use are generally collected
during ﬁxed periods of time, or combined across time
periods; neither is usually concerned with the analysis of
data over time.
Take, for example, the question of whether age and
sex are associated with the ability to undertake early
ambulation after hip surgery. Clinical researchers try to
control for such variables through the use of entry
criteria into a trial, and random assignment of patients
to experimental or control group. The usual health-
services research approach would be to use a regression
model to predict the outcome (early ambulation), over
hundreds of patients using age and sex as independent
variables. Such research could show that age and sex
predict outcomes and are statistically signiﬁcant, and
that perhaps 10% of the variance is explained by these
two independent variables. In contrast, quality-improve-
ment thinking is likely to conclude that 90% of the
variance is unexplained and could be common-cause
variation. The health-services researcher is therefore
likely to conclude that if we measured more variables,
we could explain more of this variance, while improve-
ment scientists are more likely to conclude that this
unexplained variance is a reﬂection of common-cause
variation in a good process that is under control.
The entry criteria into RCTs are carefully deﬁned,
which makes it a challenge to generalise the results
beyond the kinds of patients included in such studies.
Restricted patient entry criteria are imposed to reduce
variation in outcomes unrelated to the experimental
intervention. RCTs focus on the difference between
point estimates of outcomes for entire groups (control
and experimental), using statistical tests of signiﬁcance
to show that differences between the two arms of a trial
are not likely to be due to chance.
INDIVIDUAL PATIENTS AND THEIR HEALTHCARE
PROVIDERS
The question an individual patient asks is different from
those asked by manager and researcher, namely ‘How
can I get better?’ The answer is unique to each patient;
the question does not focus on generalising results
beyond this person. At the same time, the question
the patient’s physician is asking is whether the group
results from the best clinical trials will apply in this
patient’s case. This question calls for a different infer-
ential approach.
8e10 The cost of projecting general
ﬁndings to individual patients could be substantial, as
described below.
Consider the implications of a drug trial in which 100
patients taking a new drug and 100 patients taking
a placebo are reported as successful because 25 drug
takers improved compared with 10 controls. This
difference is shown as not likely to be due to chance.
(The drug company undertakes a multimillion dollar
advertising campaign to promote this breakthrough.)
However, on closer examination, the meaning of these
results for individual patients is not so clear. To begin
with, 75 of the patients who took the drug did not
beneﬁt. And among those 25 who beneﬁted, some,
perhaps 15, responded extremely well, while the size of
the beneﬁt in the other 10 was much smaller. To have
only the 15 ‘maximum responders’ take this drug
instead of all 100 could save the healthcare system 85%
of the drug’s costs (as well as reduce the chance of
unnecessary adverse drug effects); those ‘savings’ would,
of course, also reduce the drug company’s sales
proportionally. These considerations make it clear that
looking at more than group results could potentially
make an enormous difference in the value of research
studies, particularly from the point of view of individual
patients and their providers.
In light of the above concerns, we propose that the
longitudinal factorial study design should be the gold
standard of evidence for efﬁcacy, particularly for
assessing whether interventions whose efﬁcacy has been
established through controlled trials are effective in
individual patients for whom they might be appropriate
(box 1). Take the case of a patient with hypertension
who measures her blood pressure at least twice every day
and plots these numbers on a run chart. Through this
informal observation, she has learnt about several factors
that result in the variation in her blood pressure read-
ings: time of day, the three different hypertension
medicines she takes (not always regularly), her stress
level, eating salty French fries, exercise, meditation (and,
in her case, saying the rosary), and whether she slept
well the night before. Some of these factors she can
control; some are out of her control.
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Discovering and deﬁning sources of evidenceSince she is accustomed to monitoring her blood
pressure over time, she is in an excellent position to
carry out an experiment that would help her optimise
the effects of these various inﬂuences on her hyperten-
sion. Working with her primary care provider, she could,
for example, set up a table of randomly chosen dates to
make each of several of these changes each day, thereby
creating a systematically predetermined mix of these
controllable factors over time. This factorial design
allows her to measure the effects of individual inputs on
her blood pressure, and even interactions among them.
After an appropriate number of days (perhaps 30 days,
depending on the trade-off between urgency and statis-
tical power), she might conclude that one of her three
medications has no effect on her hypertension, and she
can stop using it. She might also ﬁnd that the combi-
nation of exercise and consistently low salt intake is as
effective as either of the other two drugs. Her answers
could well be unique to her. Planned experimental
interventions involving single patients are known as
‘N-of-1’ trials, and hundreds have been reported.
10
Although longitudinal factorial design of experiments
has long been used in quality engineering, as of 2005
there appears to have been only one published example
of its use for an individual patient.
89This method of
investigation could potentially become widely used in
the future to establish the efﬁcacy of speciﬁc drugs for
individual patients,
11 and perhaps even required,
particularly for very expensive drug therapies for chronic
conditions. Such individual trial results could be
combined to obtain generalised knowledge.
This method can be used to show (1) the independent
effect of each input on the outcome, (2) the interaction
effect between the inputs (perhaps neither drug A or B is
effective on its own, but in combination they work well),
(3) the effect of different drug dosages and (4) the lag
time between treatment and outcome. This approach
will not be practical if the outcome of interest occurs
years later. This method will be more practical with
patient access to their medical record where they could
monitor all ﬁve of Bergman’s core health processes.
12
UNDERSTANDING VARIATION IS ONE OF THE
CORNERSTONES OF THE SCIENCE OF IMPROVEMENT
This broad understanding of variation, which is based on
the work of Walter Shewart in the 1920s, goes well
beyond such simple issues as making an intended
departure from a guideline or recognising a meaningful
change in the outcome of care. It encompasses more
than good or bad variation (meeting a target). It is
concerned with more than the variation found by
researchers in random samples from large populations.
Everything we observe or measure varies. Some varia-
tion in healthcare is desirable, even essential, since each
patient is different and should be cared for uniquely.
New and better treatments, and improvements in care
processes result in beneﬁcial variation. Special-cause
variation should lead to learning. The ‘PlaneDoeStudy’
portion of the Shewhart PDSA cycle can promote valuable
change.
The ‘act’ step in the PDSA cycle represents the arrival
of stability after a successful improvement has been
made. Reducing unintended, and particularly harmful,
variation is therefore a key improvement strategy. The
more variation is controlled, the easier it is to detect
changes that are not explained by chance. Stated
differently, narrow limits on a Shewhart control chart
make it easier and quicker to detect, and therefore
respond to, special-cause variation.
The goal of statistical thinking in quality improvement
is to make the available statistical tools as simple and
useful as possible in meeting the primary goal, which is
not mathematical correctness, but improvement in both
the processes and outcomes of care. It is not fruitful to
ask whether statistical process control, RCTs, regression
equations or longitudinal factorial design of experi-
ments is best in some absolute sense. Each is appropriate
for answering different questions.
Forces driving this new way of thinking
The idea of reducing unwanted variation in healthcare
represents a major shift in thinking, and it will take time
to be accepted. Forces for this change include the
computerisation of medical records leading to public
reporting of care and outcome comparisons between
providers and around the world. This in turn will
Box 1 Longitudinal factorial design of experiments for
individual patients
The six individual components of this approach are not new,
but in combination they are new
89
1. One patient with a chronic health condition; sometimes
referred to as an ‘N-of-1 trial.’
2. Care processes and health status are measured over
time. These could include daily measures over 20 or
more days, with the patient day as the unit of analysis.
3. Whenever possible, data are numerical rather than
simple clinical observation and classiﬁcation.
4. The patient is directly involved in making therapeutic
changes and collecting data.
5. Two or more inputs (factors) are experimentally and
concurrently changed in a predetermined fashion.
6. Therapeutic inputs are added or deleted in a predeter-
mined, systematic way. For example: on day 1, drug A is
taken; on day 2, drug B; on day 3, drug A and B; day 4,
neither. For the next 4 days, this sequence could be
randomly reordered.
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Discovering and deﬁning sources of evidencepromote pay for performance, and preferred provider
contracting based on guideline use and good outcomes.
This way of thinking about variation could spread across
all ﬁve core systems of health,
12 including self-care and
processes of healthy living.
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